Scienture (SCNX) Stock Price, News & Analysis

Company Overview

Scienture Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system and other underserved medical conditions. The company’s strategy centers on differentiated medicines designed to address unmet patient and caregiver needs, including alternative formulations and delivery options.

Scienture’s lead product is ONYDA XR (clonidine hydrochloride) extended-release oral suspension, a non-stimulant prescription treatment for attention-deficit/hyperactivity disorder (ADHD). ONYDA XR is designed as a liquid formulation and may be used alone or in combination with stimulant ADHD medications, providing an option for patients who have difficulty swallowing tablets or who require a non-stimulant therapy.

The company is focused primarily on the U.S. pharmaceutical market, where it seeks to expand access to its products through commercialization, partnerships and further product development. Scienture’s portfolio and pipeline are directed toward specialty-care opportunities in which formulation, dosing flexibility or other product characteristics can provide a meaningful clinical benefit.

Key Stats

• Today's Range: $0.13 to $0.21
• 50-Day Range: $0.16 to $0.47
• 52-Week Range: $0.13 to $2.60
• Volume: 162.53 million shs
• Average Volume: 1.65 million shs
• Market Capitalization: $6.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.50
• Consensus Rating: Hold

Scienture Stock Analysis - MarketRank™

Scienture scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Scienture has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Scienture has a consensus price target of $1.50, representing about 844.6% upside from its current price of $0.16.

Amount of Analyst Coverage

Scienture has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Scienture is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scienture is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Scienture has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.87% of the float of Scienture has been sold short.

Short Interest Ratio / Days to Cover

Scienture has a short interest ratio ("days to cover") of 1.18, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scienture has recently increased by 22.27%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scienture does not currently pay a dividend.

Dividend Growth

Scienture does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.33

News Sentiment

Scienture has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Scienture this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for SCNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Scienture to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Scienture insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.51% of the stock of Scienture is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

5.68% of the stock of Scienture is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/04/2026
• AGM 2026: 10/28/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SCNX
• Previous Symbol: NASDAQ:MEDS
• CIK: 1382574
• Web: www.scienture.com
• Phone: (800) 261-0281
• Fax: 800-265-6932
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Scienture: $1.50
• High Price Target: $1.50
• Low Price Target: $1.50
• Potential Upside/Downside: +844.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$41.51 million
• Net Margins: N/A
• Pretax Margin: -8,374.42%
• Return on Equity: -53.51%
• Return on Assets: -42.47%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 3.04
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: $430 thousand
• Price / Sales: 15.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.73 per share
• Price / Book: 0.09

Miscellaneous

• Outstanding Shares: 41,060,000
• Free Float: 33,052,000
• Market Cap: $6.52 million
• Optionable: N/A
• Beta: 3.34